Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
Timothée Klopfenstein, Souheil Zayet, Anne Lohse, J.-C. Balblanc, Julio Badié, P Royer, L. Toko, Chaouki Mezher, N.J. Kadiane-Oussou, Marie Bossert, Ana-Maria Bozgan, A. Charpentier, Marie-Françoise Roux, Rémy Contreras, I. Mazurier, Pascale Dussert, Vincent Gendrin, Thierry Conrozier
Topics & Concepts
TocilizumabMedicineIntensive care unitInternal medicineRetrospective cohort studyCoronavirus disease 2019 (COVID-19)PneumoniaComorbiditySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical endpointRandomized controlled trialRheumatoid arthritisDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19